Robert W. Baird Issues Positive Forecast for Inspire Medical Systems (NYSE:INSP) Stock Price

Inspire Medical Systems (NYSE:INSP) had its price objective hoisted by equities researchers at Robert W. Baird from $73.00 to $77.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a “neutral” rating on the stock. Robert W. Baird‘s price objective suggests a potential upside of 14.04% from the stock’s previous close.

Several other brokerages have also recently weighed in on INSP. Piper Sandler upped their price target on shares of Inspire Medical Systems from $60.00 to $70.00 and gave the stock a “neutral” rating in a research report on Tuesday. Evercore set a $54.00 target price on Inspire Medical Systems in a research report on Tuesday, August 4th. Zacks Research downgraded Inspire Medical Systems from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 22nd. JPMorgan Chase & Co. boosted their price target on Inspire Medical Systems from $54.00 to $60.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Finally, UBS Group assumed coverage on Inspire Medical Systems in a research note on Tuesday, July 28th. They set a “sell” rating and a $39.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $71.24.

Inspire Medical Systems Stock Down 0.9%

INSP stock opened at $67.52 on Tuesday. The business’s fifty day simple moving average is $68.69 and its two-hundred day simple moving average is $58.82. Inspire Medical Systems has a twelve month low of $38.91 and a twelve month high of $147.03. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of 14.61, a PEG ratio of 5.37 and a beta of 0.73.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Monday, November 2nd. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.05. The company had revenue of $206.69 million for the quarter, compared to analysts’ expectations of $204.31 million. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%. Inspire Medical Systems’s revenue was down 7.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.38 earnings per share. Research analysts expect that Inspire Medical Systems will post 1.24 EPS for the current year.

Insider Activity at Inspire Medical Systems

In other news, insider Jason Kelly sold 963 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the sale, the insider owned 18,985 shares of the company’s stock, valued at $1,130,556.75. This trade represents a 4.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On Inspire Medical Systems

Institutional investors have recently added to or reduced their stakes in the business. Oregon Public Employees Retirement Fund grew its stake in shares of Inspire Medical Systems by 8.4% during the third quarter. Oregon Public Employees Retirement Fund now owns 6,462 shares of the company’s stock worth $448,000 after acquiring an additional 500 shares during the last quarter. ProShare Advisors LLC acquired a new stake in Inspire Medical Systems in the 3rd quarter worth approximately $276,000. Vise Technologies Inc. acquired a new stake in Inspire Medical Systems in the 3rd quarter worth approximately $252,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Inspire Medical Systems during the 3rd quarter worth approximately $312,000. Finally, Pinnacle Wealth Planning Services Inc. increased its stake in Inspire Medical Systems by 19.8% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 1,172 shares of the company’s stock valued at $81,000 after purchasing an additional 194 shares in the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.

Trending Headlines about Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Inspire reported third-quarter revenue of approximately $206.7 million, exceeding the $204.3 million consensus estimate. Adjusted earnings of $0.14 per share also topped published estimates of roughly $0.09–$0.10. Inspire Medical Systems Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Management’s commentary pointed toward a potential recovery in the company’s reimbursement environment, which could support procedure volumes and growth if payer-related pressures ease. Inspire Medical Tops Consensus But Misses the Whisper
• Neutral Sentiment: The earnings call was closely watched by analysts for updates on reimbursement, demand and the company’s path back to sustained growth following recent operating challenges. Inspire Medical Systems Q3 2026 Earnings Call Transcript
• Negative Sentiment: Revenue declined 7.9% from the year-ago quarter, while earnings fell to $0.14 per share from $0.38. The results indicate that reimbursement and utilization headwinds remain material despite the quarterly beat. Inspire Medical Systems Q3 Earnings and Revenues Beat Estimates
• Negative Sentiment: Although INSP exceeded official consensus forecasts, reports indicate it missed higher “whisper” expectations, limiting the positive impact of the headline earnings beat and contributing to the weaker share-price reaction. Inspire Medical Tops Consensus But Misses the Whisper

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.

Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.